UIA
BHVN

Ulland Investment Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ulland Investment Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$12K – 281
2022
Q1 		$12K Hold
100
– – 0.01% 185
2021
Q4 		$14K Buy
+100
New +$12.7K 0.01% 164

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ulland Investment Advisors's BHVN Position: Q2 2022 in Review

Ulland Investment Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 100 shares — an estimated $12K sold.

Ulland Investment Advisors first reported a position in BHVN in Q4 2021 and held it in 2 quarters. The position peaked at $14K in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Ulland Investment Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Ulland Investment Advisors sold 100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $12K.
  • Ulland Investment Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 2 quarters.
  • Ulland Investment Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14K in Q4 2021.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Ulland Investment Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.